2025-04-30 10:37:30
Latest Post
Monarch Networth Capital IFSC Pvt. Ltd. receives Registered Fund Management Entity (Retail) License from IFSCA, GIFT City
Lucent Industries Ltd enters into partnership agreement with Clusterdev Technologies Pvt Ltd
South Indian Bank hosts Season 1 of National Co-lending Summit - SEED
Inox Green signs agreement for O&M of 675 MWp of solar projects
Union Bank of India Launches MSME & CASA Outreach Programs to pass on benefits of back to back RBI-MPC rate cuts and Deepen Customer Engagement
Stock Report
Rossari Biotech Ltd reports consolidated PAT of Rs. 31.70 crores in Q3 FY2025
Posted On : 2025-01-22 22:23:48( TIMEZONE : IST )
Rossari Biotech Limited has reported Consolidated financial results for the period ended December 31, 2024.
Financial Results (Q3 FY2025) - QoQ Comparison
The company has reported total income of Rs. 513.282 crores during the period ended December 31, 2024 as compared to Rs. 499.070 crores during the period ended September 30, 2024.
The company has posted net profit / (loss) of Rs. 31.702 crores for the period ended December 31, 2024 as against net profit / (loss) of Rs. 35.333 crores for the period ended September 30, 2024.
The company has reported EPS of Rs. 5.72 for the period ended December 31, 2024 as compared to Rs. 6.38 for the period ended September 30, 2024.
| Financials | Q3 FY2025 | Q2 FY2025 | % Change |
| Total Income | ₹513.282 crs | ₹499.070 crs |  2.85% |
| Net Profit | ₹31.702 crs | ₹35.333 crs |  -10.28% |
| EPS | ₹5.72 | ₹6.38 | -10.34% |
Financial Results (Q3 FY2025) - YoY Comparison
The company has reported total income of Rs.513.282 crores during the period ended December 31, 2024 as compared to Rs.467.271 crores during the period ended December 31, 2023.
The company has posted net profit / (loss) of Rs.31.702 crores for the period ended December 31, 2024 as against net profit / (loss) of Rs.34.390 crores for the period ended December 31, 2023.
The company has reported EPS of Rs.5.72 for the period ended December 31, 2024 as compared to Rs.6.21 for the period ended December 31, 2023.
| Financials | Q3 FY2025 | Q3 FY2024 | % Change |
| Total Income | ₹513.282 crs | ₹467.271 crs | 9.85% |
| Net Profit | ₹31.702 crs | ₹34.390 crs | -7.82% |
| EPS | ₹5.72 | ₹6.21 | -7.89% |
Financial Results (9 Months Ended FY2025) - YoY Comparison
The company has reported total income of Rs.1502.950 crores during the 9 Months period ended December 31, 2024 as compared to Rs.1364.899 crores during the 9 Months period ended December 31, 2023.
The company has posted net profit / (loss) of Rs.101.934 crores for the 9 Months period ended December 31, 2024 as against net profit / (loss) of Rs.96.557 crores for the 9 Months period ended December 31, 2023.
The company has reported EPS of Rs.18.41 for the 9 Months period ended December 31, 2024 as compared to Rs.17.45 for the 9 Months period ended December 31, 2023.
| Financials | 9 Months Ended FY2025 | 9 Months Ended FY2024 | % Change |
| Total Income | ₹1502.950 crs | ₹1364.899 crs | 10.11% |
| Net Profit | ₹101.934 crs | ₹96.557 crs | 5.57% |
| EPS | ₹18.41 | ₹17.45 | 5.50% |
Shares of Rossari Biotech Limited was last trading in BSE at Rs. 757.85 as compared to the previous close of Rs. 800.95. The total number of shares traded during the day was 7443 in over 773 trades.
The stock hit an intraday high of Rs. 782.00 and intraday low of 755.00. The net turnover during the day was Rs. 5710701.00.
